Mace L. Rothenberg, MD is a physician-executive with more than 30 years of experience in government, academia, and industry. Prior to his retirement, Dr. Rothenberg served as Chief Medical Officer at Pfizer from 2019 to 2021, during which time Pfizer developed and obtained FDA authorization for the first COVID-19 vaccine. Prior to that role, Mace led Clinical Development for Oncology at Pfizer from 2008 to 2018. Over that 10 year period, his organization developed and obtained regulatory approval for 11 new cancer medicines including Ibrance® (palbociclib), a CDK 4/6 inhibitor, for patients with HR+/HER2- advanced breast cancer and Xalkori® (crizotinib) for patients with ALK+ non-small cell lung cancer. Prior to joining Pfizer, Dr. Rothenberg was Professor of Medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008. From 1991 to 1998, Mace was on faculty at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.
Dr. Rothenberg is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer and the Lane W. Adams Quality of Life Award from the American Cancer Society. He is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology. Mace currently serves on the Board of Directors for Aulos Bioscience, Tango Therapeutics, and Surrozen, as well as the Board of Overseers for the Vanderbilt-Ingram Cancer Center, the Alumni Board of Governors of the NYU Grossman School of Medicine, and the Board of Visitors for Basic Sciences at the Vanderbilt University School of Medicine.
Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from New York University in 1982. He trained in Internal Medicine at Vanderbilt and in Medical Oncology at the National Cancer Institute.